European Biotech Acquisition Corp. (NASDAQ:EBAC – Get Rating) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 800 shares, a decrease of 52.9% from the August 31st total of 1,700 shares. Based on an average daily volume of 17,100 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.
Institutional Inflows and Outflows
An institutional investor recently raised its position in European Biotech Acquisition stock. Cubist Systematic Strategies LLC grew its stake in shares of European Biotech Acquisition Corp. (NASDAQ:EBAC – Get Rating) by 136.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 60,555 shares of the company's stock after purchasing an additional 34,896 shares during the quarter. Cubist Systematic Strategies LLC's holdings in European Biotech Acquisition were worth $593,000 at the end of the most recent quarter.
Get
European Biotech Acquisition alerts:
European Biotech Acquisition Stock Down 1.5 %
Shares of EBAC traded down $0.15 during midday trading on Wednesday, hitting $9.88. 21,111 shares of the company traded hands, compared to its average volume of 29,521. The stock's 50-day moving average is $9.88. European Biotech Acquisition has a one year low of $9.66 and a one year high of $10.50.
European Biotech Acquisition Company Profile
(Get Rating)
European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands.
See Also
- Get a free copy of the StockNews.com research report on European Biotech Acquisition (EBAC)
- Can United Natural Foods Fight Both Inflation and the Fed?
- Mullen Automotive Is Ready To Get In Gear
- Cracker Barrel: A Tasty Treat Or Bad Apple?
- Defensive Stocks For A Volatile Market
- Will UPS Be Next to Deliver a Warning?
Receive News & Ratings for European Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for European Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
欧洲生物技术收购公司(纳斯达克:EBAC-GET评级)是空头股数在9月份大幅下降的目标。截至9月15日,空头股数共有800股,比8月31日的1,700股减少了52.9%。以日均成交量17,100股计算,目前天数与回补比率为0.0天。目前,该公司0.0%的股份被卖空。
机构资金流入和流出
一家机构投资者最近提高了对欧洲生物技术收购股票的头寸。据欧洲生物技术收购公司(纳斯达克代码:EBAC-GET评级)在提交给美国证券交易委员会的最新Form 13F文件中称,该公司第二季度增持该公司股份136.0%。该公司在本季度额外购买了34,896股后,持有该公司60,555股股票。截至最近一个季度末,Cubist Systems Strategy LLC在欧洲生物技术公司收购中持有的股份价值59.3万美元。
到达
收购欧洲生物技术公司警报:
欧洲生物技术收购类股下跌1.5%
在周三午盘交易中,EBAC的股价下跌了0.15美元,达到9.88美元。该公司有21,111股易手,而其平均成交量为29,521股。该股的50日移动均线切入位为9.88美元。欧洲生物技术公司的收购额一年来最低,为9.66美元,一年来最高为10.50美元。
欧洲生物技术收购公司简介
(获取评级)
欧洲生物技术收购公司没有重要的业务。公司拟与一个或者多个企业或者实体进行合并、股份交换、资产收购、股份购买、重组或者类似的业务合并。欧洲生物技术收购公司成立于2021年,总部设在荷兰阿姆斯特丹。
另请参阅
- 免费获取StockNews.com关于欧洲生物技术收购的研究报告(EBAC)
- 联合天然食品能同时对抗通胀和美联储吗?
- 马伦汽车已做好准备投入使用
- 饼干桶:可口的款待还是坏苹果?
- 防御性股票应对动荡的市场
- UPS会成为下一个发出警告的公司吗?
获得《欧洲生物技术收购日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对欧洲生物技术收购和相关公司的最新新闻和分析师评级的每日简要摘要。